The main concept here is that colorectal cancer risk in inflammatory bowel disease is driven by the amount and duration of colonic inflammation, and surveillance must be tailored to how much of the colon is involved and how long the disease has been present. Ulcerative colitis and Crohn's disease with colonic involvement both raise cancer risk, and the longer the disease has affected the colon, the higher that risk becomes. When primary sclerosing cholangitis is present with ulcerative colitis, the risk goes up even more, so surveillance is intensified in that scenario. Understanding the differences helps: UC affects the colon in a continuous way, and the risk accumulates over years of colonic exposure to inflammation. In Crohn's, if only the small bowel is involved, colorectal cancer risk is not as elevated; Crohn’s with colonic (Crohn’s colitis) behaves similarly to UC in terms of risk factors, so surveillance decisions follow extent and duration. Immunomodulators or biologics don’t erase the risk—they reduce inflammation and may lower ongoing risk, but they don’t eliminate cancer risk, so ongoing surveillance remains important. That’s why the best approach is to base surveillance on how much of the colon is involved and for how long the disease has been present, with especially careful monitoring if PSC is also present. The other statements don’t reflect these nuances: cancer risk is real in these diseases, Crohn’s with colonic involvement does increase risk, and age alone isn’t the determining factor.

CRP rises quickly in response to inflammation anywhere in the body, including the gut, making it a useful non-specific marker of intestinal inflammatory activity. It’s produced by the liver in reaction to cytokines such as IL-6, so higher levels suggest active inflammation and can help track response to treatment in inflammatory bowel disease, even though CRP doesn’t prove inflammation is confined to the intestines. Some patients with active IBD may have normal CRP, so it isn’t perfect, but it’s among the most sensitive general indicators of inflammation available. Lipase specifically signals pancreatic injury, not intestinal inflammation. Platelet count can increase with inflammation but is a broad, non-specific hematologic response rather than a direct measure of gut inflammation. Albumin can drop with chronic inflammation and malnutrition, but it changes slowly and is influenced by many factors, making it a less direct or timely marker of intestinal inflammatory activity.

The main idea is protecting an immunosuppressed patient with vaccines that are safe and effective for their status. Live vaccines contain a weakened form of a pathogen and can cause disease in someone with a suppressed immune system, so they are generally avoided when immunosuppressed. Inactivated vaccines do not contain live organisms and are safe to give, offering protection without risking infection, although the immune response may be weaker in someone on immunosuppressants. Because of that, we aim to vaccinate with inactivated vaccines whenever possible, ideally before starting immunosuppressive therapy, and continue with inactivated vaccines during treatment per the recommended schedule. The other approaches—using only vaccines during therapy, deeming vaccines unnecessary, or avoiding all vaccines—do not provide appropriate protection and aren’t appropriate strategies for someone on immunosuppressive therapy.

A pattern of eating that is high in fat and simple sugars is commonly linked with worsening IBD symptoms. Fat can influence the gut by promoting inflammation and changing the gut microbiome toward less favorable bacteria, and high-sugar foods can feed gut microbes in ways that worsen gas, diarrhea, and abdominal pain. Together, these foods often trigger flares or intensify symptoms for many people with inflammatory bowel disease, even though individual triggers can vary. Hydration is important for overall health, but it doesn’t cure symptoms. A strictly low-fiber diet is sometimes used during flares to reduce stool frequency, but it’s not something associated with exacerbation in all cases or limited to remission. Gluten avoidance isn’t necessary for most people with IBD unless there’s a coexisting gluten sensitivity or celiac disease.